Key Points
Dec 5 (Reuters) - Eli Lilly's (LLY.N) recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost customers whose health insurance does not cover the drug $550 a month, or half the list price, the company said on Tuesday...
Zepbound is the latest entrant to the fast-growing market for weight-loss drugs, which is expected to grow to about $100 billion by the end of the decade...
Zepbound has a list price of $1,059.87 a month compared with a list of $1,349 per-package for Novo Nordisk's wildly popular weight-loss drug...
Eli Lilly's shares have surged 60% this year in the run-up to the introduction of Zepbound, making the drugmaker the most valuable healthcare company in the world...
